USDA-CVB approves ECOVAXXIN® MS field safety data
Eco Animal Health Group PLC
17 September 2026
ECO Animal Health Group plc
(“ECO” or the “Company”)
USDA-CVB approves ECOVAXXIN® MS field safety data
Milestone advances poultry vaccine towards US marketing authorisation
ECO Animal Health Group plc (AIM: EAH), a leading global animal health company developing and marketing branded veterinary products to improve livestock productivity and welfare, announces that the United States Department of Agriculture, Center for Veterinary Biologics (USDA-CVB) has confirmed that ECO’s US field safety trial data for ECOVAXXIN® MS, its poultry vaccine against Mycoplasma synoviae (M. synoviae), fulfils the requirement to support licensure of the product.
The field safety trial evaluated the vaccine in more than 170,000 commercial laying pullets across three sites in Michigan, Indiana and Wisconsin. Following its assessment of the results, USDA-CVB concluded that the data fulfils the field safety requirements to support licensure, marking an important regulatory milestone for ECOVAXXIN® MS.
ECOVAXXIN® MS is the first product to emerge from ECO’s proprietary R&D pipeline and commercially launched in the EU in July 2026. Progress towards US licensure demonstrates continued pipeline delivery and supports ECO’s strategic geographical expansion of its portfolio, with US marketing approval expected for ECOVAXXIN® MS by the end of the calendar year.
David Hallas, CEO of ECO Animal Health commented: “We are delighted that the USDA-CVB has accepted the field safety data for ECOVAXXIN® MS, marking an important step forward in the US regulatory review of our Mycoplasma synoviae vaccine. This milestone reflects the strength of the data generated across the three field sites, and we are excited to continue advancing the last remaining regulatory requirements towards US marketing authorisation while simultaneously progressing the rest of our R&D pipeline to improve livestock productivity and welfare.”
-Ends-
Contacts
ECO Animal Health Group plc David Hallas (Chief Executive Officer) Christopher Wilks (Chief Financial Officer) | 020 8447 8899 |
ICR Healthcare (Financial PR) Mary-Jane Elliott Jessica Hodgson Phillip Marriage | 020 3709 5700 |
Singer Capital Markets (Nominated Adviser & Joint Broker) Jen Boorer Sara Hale James Fischer | 020 7496 3000 |
Panmure Liberum (Joint Broker) Emma Earl Will Goode Mark Rogers Rupert Dearden | 020 3100 2000 |
Equity Development Hannah Crowe Matt Evans | 020 7065 2692 |
About ECO Animal Health
ECO Animal Health (AIM: EAH) is a leading global animal health company, developing and marketing branded veterinary products that optimise livestock wellbeing and productivity.
The Group’s proprietary lead product, Aivlosin® is a market leading antibiotic for the treatment of respiratory and intestinal diseases in pigs and poultry, distributed to over 70 markets through an established commercial platform.
ECO Animal Health is also investing in the next generation of animal health products through a self-funded R&D pipeline, with a particular focus on prevention and vaccines. The first product from ECO’s pipeline, ECOVAXXIN® MS, a poultry vaccine targeting Mycoplasma synoviae infection, was commercially launched in the EU in July 2026.
Headquartered in the UK, with a global presence, ECO Animal Health employs over 200 people worldwide.
View the Group’s website or LinkedIn page for further information.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.